Literature DB >> 11117372

Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.

H R Lu1, P Remeysen, F De Clerck.   

Abstract

Selective I(Kr)- (the rapid component of the delayed rectifier potassium current) blockers are known to induce torsades de pointes (TdPs) in anesthetized rabbits during alpha1-adrenoreceptor stimulation. However, effects of nonselective I(Kr)-blockers, which produce TdPs in other animal models and in humans, are not known in this model. We examined two nonselective I(Kr)-blockers (quinidine, 1.25 mg/kg/min i.v [n = 7]; and terfenadine, 0.31 mg/kg/min i.v. [n = 7]) for their effects on electrocardiographic parameters and on incidence of cardiac arrhythmias in anesthetized rabbits during alpha1-adrenoceptor stimulation with methoxamine. We compared the drugs with two highly selective I(Kr)-blockers (dofetilide, 0.04 mg/kg/min i.v. [n = 7]; and clofilium, 0.08 mg/kg/min i.v. [n = 6]). Polymorphic ventricular tachycardia or TdPs were induced by dofetilide and clofilium at mean doses > or =0.33 mg/kg and 0.4 mg/kg i.v., in all animals tested (vs. none in solvent; p < 0.05). TdPs usually developed into ventricular fibrillation and developed after prolongation of QT/JT interval and of QT dispersion. Terfenadine and quinidine significantly increased PQ, QT, and QTc interval and largely increased QRS duration and QT dispersion. These compounds elicited intraventricular conduction defects and cardiac arrest, due to asystole, in all animals tested (vs. 0% in solvent; p < 0.05). Interestingly, these two nonselective I(Kr)-blockers did not produce TdPs or ventricular fibrillation in any animals tested. Our results thus indicate that selective I(Kr)-blockers elicit TdPs, whereas nonselective I(Kr)-blockers do not induce this type of arrhythmia in this rabbit model. Consequently, it should be noted that this rabbit model is not always useful to evaluate nonselective I(Kr)-blocker-induced TdPs and QT interval and QT dispersion, rather than TdPs, are also important indicators for drug-induced cardiac arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117372     DOI: 10.1097/00005344-200012000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Drugs, QT interval prolongation and ICH E14: the need to get it right.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in α(1) -adrenoceptor-stimulated, anaesthetized rabbits.

Authors:  Attila S Farkas; László Rudas; Péter Makra; Norbert Csík; István Leprán; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

4.  Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.

Authors:  Andrew J Batey; Susan J Coker
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 5.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

6.  Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.

Authors:  A Farkas; J Dempster; S J Coker
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

7.  Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs.

Authors:  G Michael; K A Kane; S J Coker
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

Review 8.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 9.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 10.  Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.

Authors:  M A Vos
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.